Considerable interest surrounds the use of immune-checkpoint inhibitors in patients with
solid tumours following the demonstration of the impressive clinical efficacy of anti …

Response evaluation for cancer treatment consists primarily of clinical and radiological
assessments. In addition, a limited number of serum biomarkers that assess treatment …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

Background Recent clinical results support the use of new immune checkpoint blockers
(ICB), such as anti-PD-1 (eg nivolumab and pembrolizumab) and anti-PD-L1 antibodies …

The therapeutic landscape for patients with advanced malignancies has changed
dramatically over the last twenty years. The growing number of targeted therapies and …

Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Abstract Purpose: Treatment with PD-(L) 1 blockade can produce remarkably durable
responses in patients with non–small cell lung cancer (NSCLC). However, a significant …